. We are a molecular diagnostics company with unique technology for improving the care of patients with genetic diseases.
We have developed proprietary biomarkers and novel diagnostic test methods to identify hereditary gene mutations using tissue biopsy samples. This allows optimum treatment decision-making at the time of biopsy leading to improved patient outcomes.
Our tests will establish a new paradigm for screening for genetic disease by offering a quick, easy, accurate and cost-effective diagnosis that provides significant benefits for the patient, physician and insurance carrier.
Market Need
Poorly diagnosed diseases are not treated properly, timely or economically.
Current methods to diagnose genetic diseases are complex, expensive and time-consuming. The shortcomings in current diagnostic approaches mean that most people with genetic diseases are either not properly identified or found too late and at great expense. The result is an underserved market, adversely affecting patient outcome.
Our technology directly provides improved patient outcomes at lower costs.
The Company
The company was founded to commercialize novel technologies developed in the lab of Dr. Jeffrey Holt, Professor at the University of Colorado Health Sciences Center. Dr. Holt has spent 30 years in cancer research and was part of the team that identified the function of the BRCA gene.The company has an exclusive license for the breadth of proprietary technologies developed by Dr. Holt at the University of Colorado Health Sciences Center.
